Medisan Pharmaceutical Co.,Ltd.LANXI

Main research purpose: This study uses Olopatadine Hydrochloride Granules (Specification: 2.5 mg) produced by Lanxiha Sanlian Pharmaceutical Co., Ltd. as the test preparation, and Olopatadine Hydrochloride Granules [Specification: 0.5% (2.5 mg/0.5 g), trade name: Allelock®] produced by the original manufacturer Kyowa Kirin Co., Ltd. as the reference preparation to evaluate the bioequivalence of the test preparation and the reference preparation after administration under postprandial conditions. Secondary research purpose: To observe the safety of a single oral dose of 2.5 mg of Olopatadine Hydrochloride Granules test preparation or reference preparation in healthy subjects.

Main research purpose: This study used olopatadine hydrochloride granules (specification: 2.5 mg) produced by Lanxiha Sanlian Pharmaceutical Co., Ltd. as the test preparation, and olopatadine hydrochloride granules [specification: 0.5% (2.5 mg/0.5 g), trade name: Allelock®] produced by the original manufacturer Kyowa Kirin Co., Ltd. as the reference preparation to evaluate the bioequivalence of the test preparation and the reference preparation after administration under fasting conditions. Secondary study objective: To observe the safety of a single oral administration of 2.5 mg of the test preparation or reference preparation of olopatadine hydrochloride granules in healthy subjects.

Primary objective: To explore and evaluate the clinical efficacy of loxoprofen sodium gel patch in the treatment of knee osteoarthritis using active drugs and placebo as controls. Secondary objective: To evaluate the safety of loxoprofen sodium gel patch in patients with knee osteoarthritis pain.